These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9633686)

  • 1. Levodopa neurotoxicity: experimental studies versus clinical relevance.
    Jenner PG; Brin MF
    Neurology; 1998 Jun; 50(6 Suppl 6):S39-43; discussion S44-8. PubMed ID: 9633686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?
    Ziv I; Zilkha-Falb R; Offen D; Shirvan A; Barzilai A; Melamed E
    Mov Disord; 1997 Jan; 12(1):17-23. PubMed ID: 8990049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa toxicity and apoptosis.
    Melamed E; Offen D; Shirvan A; Djaldetti R; Barzilai A; Ziv I
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S149-54. PubMed ID: 9749587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?
    Murer MG; Raisman-Vozari R; Gershanik O
    Drug Saf; 1999 Nov; 21(5):339-52. PubMed ID: 10554050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease.
    Schapira AH
    Mov Disord; 2008; 23 Suppl 3():S515-20. PubMed ID: 18781678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is levodopa toxic?
    Müller T; Hefter H; Hueber R; Jost WH; Leenders KL; Odin P; Schwarz J
    J Neurol; 2004 Sep; 251 Suppl 6():VI/44-6. PubMed ID: 15675725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress.
    Mytilineou C; Walker RH; JnoBaptiste R; Olanow CW
    J Pharmacol Exp Ther; 2003 Feb; 304(2):792-800. PubMed ID: 12538835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of control mechanisms of dopamine-induced apoptosis--a future approach to the treatment of Parkinson's disease?
    Ziv I; Offen D; Barzilai A; Haviv R; Stein R; Zilkha-Falb R; Shirvan A; Melamed E
    J Neural Transm Suppl; 1997; 49():195-202. PubMed ID: 9266428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.
    Kariya S; Takahashi N; Hirano M; Ueno S
    J Mol Neurosci; 2005; 27(3):277-79. PubMed ID: 16280597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
    Takashima H; Tsujihata M; Kishikawa M; Freed WJ
    Exp Neurol; 1999 Sep; 159(1):98-104. PubMed ID: 10486178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
    Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
    Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of dopaminergic agents in Parkinson's disease.
    Koller WC; Rueda MG
    Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
    Lang AE; Obeso JA
    Lancet Neurol; 2004 May; 3(5):309-16. PubMed ID: 15099546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.